• Peripheral Arterial Disease Screening System

      Bio-tech & New Drugs FutureTech Peripheral Arterial Disease Screening System

      In Taiwan, there are almost 96 million people look for medical treatment due to diabetes. The project successfully used the infrared light measurement system to observe the differences between the bilateral feet,collocating with the Chaos Synchronization to measure the differences between different signals, to decrease the probability of the attendance as the ultimate objective .
    • Mobile Application for Anti-Doping & Gastroenteritis Defender

      Bio-tech & New Drugs FutureTech Mobile Application for Anti-Doping & Gastroenteritis Defender

      1. ‘Mobile Application for Anti-Doping’ containing more than 40,000 pharmaceuticals which allows athletes to check whether the pharmaceuticals are prohibited in-out-of-competition simply via typing in the product names. 2. ‘Gastroenteritis Defender’ utilizes nanotechnology to enhance andrographolide oral bioavailabilitycould effectively prevent gastrointestinal inflammatory disorders.
    • Develop of novel anti-diabetic agents via targeting endogenous lipid mediators

      Bio-tech & New Drugs FutureTech Develop of novel anti-diabetic agents via targeting endogenous lipid mediators

      PPARγ is the master regulator of glucose metabolism.15-keto-PGE2 is an endogenous PPARγ ligand whitch is degraded by ZADH1. We found that increasing 15-keto-PGE2 promotes glucose uptake. We identified several ZADH1 inhibitors which could increase 15-keto-PGE2 promote glucose uptake via activating PPARγ. Our results showed that inhibition of ZADH1 is a novel approach to treat type 2 diabes mell
    • RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT

      Bio-tech & New Drugs FutureTech RSV VACCINE COMPOSITION COMPRISING HEPATITIS B VIRUS-LIKE PARTICLES AS ADJUVANT

      In this project, we have reorganized several highly immunogenic sitesstructurally essential regions to maintain it in a pre-fusion stateuse it as main antigen in our RSV vaccine candidate (RSV-F005). To induce a mucosal immune response, intranasal administration route was chosen. New mucosal adjuvant (H-muad) has been tested in threee animal models.
    • A therapeutic gel for diabetic wounds

      Bio-tech & New Drugs FutureTech A therapeutic gel for diabetic wounds

      Our results have demonstrated that our tissue gel can effectively promote angiogenesiswound healing in diabetic wounds. Our product prototype will be a powerful therapeutic product to treat diabetic foot ulcersgo further to rescue diabetic patients from amputation.
    • Composition for treating lung fibrosisemphysematherapeutic method using the same

      Bio-tech & New Drugs FutureTech Composition for treating lung fibrosisemphysematherapeutic method using the same

      This is a regenerative biomedical technology, which aims to address the human chronic lung diseases that currently has no pharmaceutical approach for efficient controltherapy, such as COPDlung fibrosis. The principle is to induce the in vivo reprogramming of endogenous alveolar epithelial cells through activation of stemness factor BMI1, which potentiates the repair of injured tissues.
    • An Anti-Obesity Nanotechnology to Modulate Oil Absorption In Vivo

      Bio-tech & New Drugs FutureTech An Anti-Obesity Nanotechnology to Modulate Oil Absorption In Vivo

      This technology is mainly solved the side effects of anti-obesity drug, including soft stoolsoily stools,regulate oil absorptionmetabolism as an additive in food. During the experiment, the curing phenomenon of MSNs/oiloily stool reduction in animal were observed. In conclusion, MSNs can effectively reduce the side effects of Orlistatelevating life quality.
    • A genomic marker guided roadmap to treat hepatocellular carcinoma

      Bio-tech & New Drugs FutureTech A genomic marker guided roadmap to treat hepatocellular carcinoma

      This is a method for identifying single nucleotide polymorphisms (GALNT14 genotypes) of a target nucleic acid for predicting whether a patient suffering from HCC will respond to combination chemotherapy. Accordingly, physicians can decide whether the HCC patients should receive chemotherapyTACE. This method could also predict prognosis in multiple gastrointestinal cancers.
    • Bi-specific antibodiesuses thereof

      Bio-tech & New Drugs FutureTech Bi-specific antibodiesuses thereof

      We developed a humanized bifunctional antibody (mPEG×tumor marker),the anti-PEG end can be non-covalently modified to bind any PEGylated nano-druga contrast agent by one-step "formulation". The non-covalent binding solved the problems of chemical modification such as the masking of the antibody binding site, heterogeneity, drug instability. The other end of the bifunctional antibody can specifical
    • Modular Polymeric Nanoshells for Precision AntiviralAnticancer Vaccination

      Bio-tech & New Drugs FutureTech Modular Polymeric Nanoshells for Precision AntiviralAnticancer Vaccination

      Effectively inducing cytotoxic T cell expansion has been a critical challenge in vaccine development. To address this challenge, an entirely biodegradable polymeric nanoshell was invented to couple antigensadjuvants for safepotent immune potentiation. The invention has been adopted for precision anticancer vaccine, broadly reactive influenza vaccine,an effective vaccine MERS-CoV.
    • Novel nano-hydrogel technology on medicine, biomaterial, foodcosmetics

      Bio-tech & New Drugs Innotech Expo Novel nano-hydrogel technology on medicine, biomaterial, foodcosmetics

      1. A novel three-dimensional skin equivalent 2. A supercritical extraction system preserves bioactivity: no toxicity, environmental friendly, high efficiency, refine efficient biological elements 3. Advantages of hydrogel: large area ‎30 s quick-drying coolpain-killing transparentdifficult to observe moisturization tensioncontraction biodegradation easy to clean / makeup
  • 1